Finally and perhaps most importantly, we establish that expression of CD26/DPPIV resulted in enhanced levels of topoisomerase II α that correlated with increased enzyme activity, suggesting a potential mechanism for the observed increase in tumour sensitivity to the topoisomerase II inhibitors doxorubicin and etoposide. The gene discussed is DPP4; the disease is neoplasm.